TAS5315, BTK inhibitor, studied in 91 MTX refractory RA pts. Wk 12 ACR20 resp was 79% on TAS5315 vs 60% PBO (p=0.053); ACR50 (33 vs 13%) not signif. Adverse event equal betw grps, but 9 pts had bleeding on TAS5315 https://t.co/XYS0XRMJar https://t.co/ntGtahFf4T